Carboplatin News and Research

RSS

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).

FDA grants approval for new biosimilar to treat multiple types of cancer

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

14 Sep 2017

Study: Chemoradiation should remain standard treatment for locally advanced cervical cancer

A 14-year randomised trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings are reported today at the ESMO 2017 Congress in Madrid. The trial demonstrated no improved disease-free survival with neoadjuvant chemotherapy followed by surgery.

11 Sep 2017

Trial confirms standard three-week dosing of chemotherapy as first line treatment in ovarian cancer

European women with ovarian cancer can safely stick to the standard three-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be presented at the ESMO 2017 Congress in Madrid.

4 Sep 2017

FDA approves expanded use of Zykadia for first-line treatment of ALK-positive metastatic NSCLC

Novartis today announced the US Food and Drug Administration approved the expanded use of Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.

27 May 2017

Researchers identify DNA repair deficiency in many types of solid tumors

A new investigation of more than 48,000 stored tumor samples finds evidence of a key deficiency in a repair mechanism designed to keep DNA from being mutated and causing cancer.

18 May 2017

Combination therapy may be effective option for treating some women with ovarian cancer

Researchers have been trying to understand why up to 85 percent of women experience recurrence of high-grade serous ovarian cancer -- the most common subtype of ovarian cancer -- after standard treatment with the chemotherapy drug carboplatin.

2 May 2017

ASTRO issues new clinical guideline for management of oropharyngeal cancer with radiation therapy

The American Society for Radiation Oncology today issued a new clinical guideline for the management of oropharyngeal cancer.

17 Apr 2017

KU researcher reveals possible therapeutic intervention for 'chemobrain' in cancer patients

Findings offered by a University of Kansas researcher, identified as one of 20 'Must See Presenters' at the national meeting of the American Chemical Society in early April, suggest a possible therapeutic intervention for "chemobrain," the cognitive impairment plaguing up to a third of cancer patients following chemotherapy.

12 Apr 2017

Study finds biochemical pathway that triggers regrowth of breast cancer stem cells after chemotherapy

Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.

22 Feb 2017

Study addresses cost-effectiveness of checkpoint inhibitors for advanced melanoma in Hong Kong

Immunotherapy with pembrolizumab has been deemed a cost-effective first line treatment for advanced melanoma patients in Hong Kong, researchers report at the ESMO Asia 2016 Congress in Singapore.

17 Dec 2016

I-SPY2 research initiative employs exciting new model for testing breast cancer drugs

In a new paradigm of breast cancer research, physicians are fast-tracking promising new experimental drugs for further study, while immediately dropping drugs and drug combinations that don't work.

8 Jul 2016

First-line nivolumab promising in advanced NSCLC

Phase I results published in the Journal of Clinical Oncology suggest that nivolumab, either given alone or alongside platinum-based doublet chemotherapy, could have a role in the first-line treatment of advanced non-small-cell lung cancer.

5 Jul 2016

Tandem myeloablative ASCT consolidation boosts neuroblastoma outcomes

Research presented at the American Society of Clinical Oncology annual conference suggests that consolidation therapy with tandem compared with single myeloablative autologous stem cell transplant can improve outcomes in paediatric patients with high-risk neuroblastoma.

12 Jun 2016

Drug candidate delivered by plant-virus-based carrier shows promise for triple-negative breast cancer

In a pair of firsts, researchers at Case Western Reserve University and Massachusetts Institute of Technology have shown that the drug candidate phenanthriplatin can be more effective than an approved drug in vivo, and that a plant-virus-based carrier successfully delivers a drug in vivo.

9 Jun 2016

Novel drug atezolizumab harnesses immune system to shrink tumors in advanced bladder cancer

A new drug that harnesses the immune system to attack tumors is highly effective against advanced bladder cancer, according to the results of an international clinical trial to be presented June 5 at the annual meeting of the American Society for Clinical Oncology.

6 Jun 2016

Fasnall drug appears to inhibit tumor growth by promoting cancer cell death

A promising new compound appears to impede a process that fuels breast cancer in mice, a discovery that could have implications in the treatment of a host of cancers.

3 Jun 2016

Researchers find new clue to understanding 'chemo brain' in cancer patients

During and after chemotherapy, many cancer patients describe feeling a mental fog, a condition that has been dubbed "chemo brain." Why this happens is unclear, but researchers have found a new clue to understanding this syndrome.

26 May 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

Survivin inhibitor with chemotherapy provides therapeutic advantage for Rb cells, tumors

Researchers at The Saban Research Institute of Children's Hospital Los Angeles (CHLA) have demonstrated that targeting survivin - a protein that inhibits apoptosis or cell death - enhances the effectiveness of chemotherapy in cells and mouse models of retinoblastoma (Rb), the most common malignant tumor of the eye in children.

18 Apr 2016

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic lymphoma kinase (ALK) and have already received another treatment. In November 2015, the approval was extended to first-line treatment.

11 Apr 2016